Base de dados : MEDLINE
Pesquisa : D02.241.081.251.510 [Categoria DeCS]
Referências encontradas : 1112 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 112 ir para página                         

  1 / 1112 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27798072
[Au] Autor:Lu A; Scott KS; Chan-Hosokawa A; Logan BK
[Ad] Endereço:Arcadia University, Department of Chemistry, 450 S. Easton Road, Glenside, PA 19038, USA.
[Ti] Título:Impact of Expanding ELISA Screening in DUID Investigations to Include Carisoprodol/Meprobamate and Zolpidem.
[So] Source:J Anal Toxicol;41(2):134-139, 2017 Mar 01.
[Is] ISSN:1945-2403
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:In 2013, the National Safety Council's Alcohol Drugs and Impairment Division added zolpidem and carisoprodol and its metabolite meprobamate to the list of Tier 1 drugs that should be tested for in all suspected drug impaired driving and motor vehicle fatality investigations. We describe the validation of an enzyme linked immunosorbent assays (ELISA) for both drugs in whole blood, and the utilization of the ELISA to assess their positivity in a sample of 322 suspected impaired driving cases that was retrospectively screened using the validated assays. The occurrence of carisoprodol/meprobamate was found to be 1.2%, and for zolpidem, 1.6%. In addition, we analyzed a large dataset (n = 1,672) of Driving Under the Influence of Drugs (DUID) test results from a laboratory performing high volume DUID testing to assess the frequency of detection of both drugs after implementing the expanded NSC scope. Carisoprodol or meprobamate were found positive in 5.9% (n = 99) of these samples, while zolpidem was found positive in 5.3% (n = 89) in drivers who in many cases had been found to be negative for other drugs. Carisoprodol and zolpidem are both potent CNS depressants and are appropriate additions to the recommended NSC scope of testing.
[Mh] Termos MeSH primário: Condução de Veículo
Carisoprodol/sangue
Depressores do Sistema Nervoso Central/sangue
Dirigir sob a Influência/estatística & dados numéricos
Meprobamato/sangue
Piridinas/sangue
Detecção do Abuso de Substâncias
[Mh] Termos MeSH secundário: Dirigir sob a Influência/legislação & jurisprudência
Ensaio de Imunoadsorção Enzimática
Regulamentação Governamental
Seres Humanos
Estudos Retrospectivos
Detecção do Abuso de Substâncias/legislação & jurisprudência
Detecção do Abuso de Substâncias/métodos
Detecção do Abuso de Substâncias/estatística & dados numéricos
Estados Unidos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Central Nervous System Depressants); 0 (Pyridines); 21925K482H (Carisoprodol); 7K383OQI23 (zolpidem); 9I7LNY769Q (Meprobamate)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:170525
[Lr] Data última revisão:
170525
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161101
[St] Status:MEDLINE
[do] DOI:10.1093/jat/bkw106


  2 / 1112 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26976315
[Au] Autor:Lounis Y; Bonnet-Zamponi D; Pautas É; Gaubert-Dahan ML
[Ad] Endereço:GH Hôpitaux universitaires Paris-Ouest, AP-HP, Hôpital Vaugirard, service de gérontologie, 10 rue Vaugelas, 75015 Paris, France.
[Ti] Título:[What happened after meprobamate's withdrawal? Survey in two nursing homes].
[Ti] Título:Enquête dans deux Ehpad sur le retrait du méprobamate..
[So] Source:Soins Gerontol;(118):26-30, 2016 Mar-Apr.
[Is] ISSN:1268-6034
[Cp] País de publicação:France
[La] Idioma:fre
[Ab] Resumo:We have conducted in two nursing homes a survey to study the impact of meprobamate's withdrawal, at the beginning of 2012, in terms of extent of prescribing to others psychotropic drugs and occurrence of adverse events. After meprobamate's withdrawal, 65 % of residents did not receive alternative medication and within three months after meprobamate stopping, adverse events (drowsiness, falls and hospitalization) decreased while agitation did not increase.
[Mh] Termos MeSH primário: Ansiolíticos/efeitos adversos
Meprobamato/efeitos adversos
Casas de Saúde
[Mh] Termos MeSH secundário: Idoso de 80 Anos ou mais
Uso de Medicamentos/estatística & dados numéricos
Feminino
França
Seres Humanos
Prescrição Inadequada
Masculino
Estudos Retrospectivos
Retirada de Medicamento Baseada em Segurança
[Pt] Tipo de publicação:ENGLISH ABSTRACT; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Anxiety Agents); 9I7LNY769Q (Meprobamate)
[Em] Mês de entrada:1606
[Cu] Atualização por classe:160315
[Lr] Data última revisão:
160315
[Sb] Subgrupo de revista:N
[Da] Data de entrada para processamento:160316
[St] Status:MEDLINE


  3 / 1112 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26929223
[Au] Autor:James AO; Nicholson TR; Hill R; Bearn J
[Ad] Endereço:South London and Maudsley NHS Trust, London, UK.
[Ti] Título:Something old, something new: a successful case of meprobamate withdrawal.
[So] Source:BMJ Case Rep;2016, 2016 Feb 29.
[Is] ISSN:1757-790X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Meprobamate, a benzodiazepine-like drug, was commonly prescribed for anxiety in the 1960s and 1970s, but fell out of favour, at least in part, due to the risk of dependence, for which there is little published evidence to guide clinical management. We discuss a 70-year-old man with a 45-year history of meprobamate dependency and multiple failed previous withdrawal attempts who was successfully withdrawn from meprobamate using diazepam during a 2-week inpatient stay on a specialist Addictions ward. An appropriate diazepam dose was established using the Clinical Institute Withdrawal Assessment scale for benzodiazepines (CIWA-B). This dose was then slowly reduced over 12 days. Multidisciplinary input, especially psychological therapy tackling his underlying anxiety disorder during his admission, was thought to be particularly helpful.
[Mh] Termos MeSH primário: Diazepam/administração & dosagem
Meprobamato/administração & dosagem
Síndrome de Abstinência a Substâncias/tratamento farmacológico
[Mh] Termos MeSH secundário: Idoso
Transtornos de Ansiedade/tratamento farmacológico
Diazepam/uso terapêutico
Relação Dose-Resposta a Droga
Seres Humanos
Pacientes Internados
Masculino
Meprobamato/efeitos adversos
Síndrome de Abstinência a Substâncias/etiologia
Resultado do Tratamento
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
9I7LNY769Q (Meprobamate); Q3JTX2Q7TU (Diazepam)
[Em] Mês de entrada:1612
[Cu] Atualização por classe:170922
[Lr] Data última revisão:
170922
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160302
[St] Status:MEDLINE


  4 / 1112 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26872987
[Au] Autor:Kumar M; Dillon GH
[Ad] Endereço:Department of Physiology and Pharmacology and Center for Neuroscience, Robert C. Byrd Health Sciences Center, West Virginia University, Morgantown, WV, USA.
[Ti] Título:Assessment of direct gating and allosteric modulatory effects of meprobamate in recombinant GABA(A) receptors.
[So] Source:Eur J Pharmacol;775:149-58, 2016 Mar 15.
[Is] ISSN:1879-0712
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Meprobamate is a schedule IV anxiolytic and the primary metabolite of the muscle relaxant carisoprodol. Meprobamate modulates GABAA (γ-aminobutyric acid Type A) receptors, and has barbiturate-like activity. To gain insight into its actions, we have conducted a series of studies using recombinant GABAA receptors. In αxßzγ2 GABAA receptors (where x=1-6 and z=1-3), the ability to enhance GABA-mediated current was evident for all α subunit isoforms, with the largest effect observed in α5-expressing receptors. Direct gating was present with all α subunits, although attenuated in α3-expressing receptors. Allosteric and direct effects were comparable in α1ß1γ2 and α1ß2γ2 receptors, whereas allosteric effects were enhanced in α1ß2 compared to α1ß2γ2 receptors. In "extrasynaptic" (α1ß3δ and α4ß3δ) receptors, meprobamate enhanced EC20 and saturating GABA currents, and directly activated these receptors. The barbiturate antagonist bemegride attenuated direct effects of meprobamate. Whereas pentobarbital directly gated homomeric ß3 receptors, meprobamate did not, and instead blocked the spontaneously open current present in these receptors. In wild type homomeric ρ1 receptors, pentobarbital and meprobamate were ineffective in direct gating; a mutation known to confer sensitivity to pentobarbital did not confer sensitivity to meprobamate. Our results provide insight into the actions of meprobamate and parent therapeutic agents such as carisoprodol. Whereas in general actions of meprobamate were comparable to those of carisoprodol, differential effects of meprobamate at some receptor subtypes suggest potential advantages of meprobamate may be exploited. A re-assessment of previously synthesized meprobamate-related carbamate molecules for myorelaxant and other therapeutic indications is warranted.
[Mh] Termos MeSH primário: Ansiolíticos/farmacologia
Moduladores GABAérgicos/farmacologia
Meprobamato/farmacologia
Relaxantes Musculares Centrais/farmacologia
Subunidades Proteicas/fisiologia
Receptores de GABA-A/fisiologia
[Mh] Termos MeSH secundário: Bemegrida/farmacologia
Carisoprodol/farmacologia
Células HEK293
Seres Humanos
Ativação do Canal Iônico/efeitos dos fármacos
Pentobarbital/farmacologia
Subunidades Proteicas/genética
Receptores de GABA-A/genética
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL
[Nm] Nome de substância:
0 (Anti-Anxiety Agents); 0 (GABA Modulators); 0 (Muscle Relaxants, Central); 0 (Protein Subunits); 0 (Receptors, GABA-A); 21925K482H (Carisoprodol); 57DQA39DO2 (Bemegride); 9I7LNY769Q (Meprobamate); I4744080IR (Pentobarbital)
[Em] Mês de entrada:1612
[Cu] Atualização por classe:170315
[Lr] Data última revisão:
170315
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160214
[St] Status:MEDLINE


  5 / 1112 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26660179
[Au] Autor:Slawson MH; Johnson-Davis KL
[Ad] Endereço:ARUP Institute for Clinical and Experimental Pathology, 500 Chipeta Way, Salt Lake City, UT, 84108, USA.
[Ti] Título:Quantitation of Carisoprodol and Meprobamate in Urine and Plasma Using Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS).
[So] Source:Methods Mol Biol;1383:105-14, 2016.
[Is] ISSN:1940-6029
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Carisoprodol and meprobamate are centrally acting muscle relaxant/anxiolytic drugs that can exist in a parent-metabolite relationship (carisoprodol → meprobamate) or as a separate pharmaceutical preparation (meprobamate aka Equanil, others). The monitoring of the use of these drugs has both clinical and forensic applications in pain management applications and in overdose situations. LC-MS/MS is used to analyze urine or plasma/serum extracts with deuterated analogs of each analyte as internal standards to ensure accurate quantitation and control for any potential matrix effects. Positive ion electrospray is used to introduce the analytes into the mass spectrometer. Selected reaction monitoring of two product ions for each analyte allows for the calculation of ion ratios which ensures correct identification of each analyte, while a matrix-matched calibration curve is used for quantitation.
[Mh] Termos MeSH primário: Carisoprodol/sangue
Carisoprodol/urina
Meprobamato/sangue
Meprobamato/urina
Relaxantes Musculares Centrais/sangue
Relaxantes Musculares Centrais/urina
Espectrometria de Massas em Tandem/métodos
[Mh] Termos MeSH secundário: Cromatografia Líquida/métodos
Seres Humanos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Muscle Relaxants, Central); 21925K482H (Carisoprodol); 9I7LNY769Q (Meprobamate)
[Em] Mês de entrada:1610
[Cu] Atualização por classe:161230
[Lr] Data última revisão:
161230
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:151215
[St] Status:MEDLINE
[do] DOI:10.1007/978-1-4939-3252-8_12


  6 / 1112 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:25324526
[Au] Autor:Knittel JL; Vorce SP; Levine B; Hughes RL; Bosy TZ
[Ad] Endereço:Division of Forensic Toxicology, Armed Forces Medical Examiner System, Dover AFB, Dover, DE 19902, USA jessica.l.knittel.ctr@mail.mil.
[Ti] Título:Multidrug toxicity involving sumatriptan.
[So] Source:J Anal Toxicol;39(1):75-9, 2015 Jan-Feb.
[Is] ISSN:1945-2403
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:A multidrug fatality involving sumatriptan is reported. Sumatriptan is a tryptamine derivative that acts at 5-HT(1B/1D) receptors and is used for the treatment of migraines. The decedent was a 21-year-old white female found dead in bed by her spouse. No signs of physical trauma were observed and a large number of prescription medications were discovered at the scene. Toxicological analysis of the central blood revealed sumatriptan at a concentration of 1.03 mg/L. Following therapeutic dosing guidelines, sumatriptan concentrations do not exceed 0.095 mg/L. Sumatriptan was isolated by solid-phase extraction and analyzed using liquid chromatography-tandem mass spectrometry in multiple reaction monitoring mode. A tissue distribution study was completed with the following concentrations measured: 0.61 mg/L in femoral blood, 0.56 mg/L in iliac blood, 5.01 mg/L in urine, 0.51 mg/kg in liver, 3.66 mg/kg in kidney, 0.09 mg/kg in heart, 0.32 mg/kg in spleen, 0.01 mg/kg in brain, 15.99 mg/kg in lung and 78.54 mg/45 mL in the stomach contents. Carisoprodol, meprobamate, fluoxetine, doxylamine, orphenadrine, dextromethorphan and hydroxyzine were also present in the blood at the following concentrations: 3.35, 2.36, 0.63, 0.19, 0.06, 0.55 and 0.16 mg/L. The medical examiner ruled the cause of death as acute mixed drug toxicity and the manner of death as accident.
[Mh] Termos MeSH primário: Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos/sangue
Sumatriptana/envenenamento
[Mh] Termos MeSH secundário: Autopsia
Carisoprodol/sangue
Cromatografia Líquida
Dextrometorfano/sangue
Doxilamina/sangue
Estudos de Avaliação como Assunto
Evolução Fatal
Feminino
Fluoxetina/sangue
Toxicologia Forense
Seres Humanos
Hidroxizina/sangue
Fígado/efeitos dos fármacos
Fígado/metabolismo
Meprobamato/sangue
Orfenadrina/sangue
Reprodutibilidade dos Testes
Manejo de Espécimes
Sumatriptana/farmacocinética
Espectrometria de Massas em Tandem
Distribuição Tecidual
Adulto Jovem
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
01K63SUP8D (Fluoxetine); 21925K482H (Carisoprodol); 30S50YM8OG (Hydroxyzine); 7355X3ROTS (Dextromethorphan); 8R78F6L9VO (Sumatriptan); 95QB77JKPL (Doxylamine); 9I7LNY769Q (Meprobamate); AL805O9OG9 (Orphenadrine)
[Em] Mês de entrada:1510
[Cu] Atualização por classe:150113
[Lr] Data última revisão:
150113
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:141018
[St] Status:MEDLINE
[do] DOI:10.1093/jat/bku120


  7 / 1112 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:24798495
[Au] Autor:Dong MM; Trenholm R; Rosario-Ortiz FL
[Ad] Endereço:Civil, Environmental and Architectural Engineering, 428 UCB, University of Colorado, Boulder, CO 80309, USA; Southern Nevada Water Authority (SNWA), P.O. Box 99954, Las Vegas, NV 89193-9954, USA.
[Ti] Título:Photochemical degradation of atenolol, carbamazepine, meprobamate, phenytoin and primidone in wastewater effluents.
[So] Source:J Hazard Mater;282:216-23, 2015 Jan 23.
[Is] ISSN:1873-3336
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:The photochemical degradation of five pharmaceuticals was examined in two secondary wastewater effluents. The compounds, which included atenolol, carbamazepine, meprobamate, phenytoin and primidone, were evaluated for both direct and sensitized photolysis. In the two wastewaters, direct photolysis did not lead to significant compound degradation; however, sensitized photolysis was an important removal pathway for the five pharmaceuticals. Upon solar irradiation, hydroxyl radical (HO) was quantified using the hydroxylation of benzene and singlet oxygen ((1)O2) formation was monitored following the degradation of furfuryl alcohol. Degradation via sensitized photolysis was observed following five-day exposures for atenolol (69-91%), carbamazepine (67-98%), meprobamate (16-52%), phenytoin (44-85%), and primidone (34-88%). Varying removal is likely a result of the differences in reactivity with transient oxidants. Averaged steady state HO concentrations ranged from 1.2 to 4.0×10(-16)M, whereas the concentrations of (1)O2 were 6.0-7.6×10(-14)M. Partial removal due to presence of HO indicates it was not the major sink for most compounds examined. Other transient oxidants, such as (1)O2 and triplet state effluent organic matter, are likely to play important roles in fates of these compounds.
[Mh] Termos MeSH primário: Radical Hidroxila/química
Luz Solar
Poluentes Químicos da Água/química
Poluentes Químicos da Água/efeitos da radiação
[Mh] Termos MeSH secundário: Atenolol/química
Carbamazepina/química
Meprobamato/química
Oxidantes/química
Fenitoína/química
Fotólise
Primidona/química
Oxigênio Singlete/química
Eliminação de Resíduos Líquidos/métodos
Águas Residuais/química
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T; RESEARCH SUPPORT, U.S. GOV'T, NON-P.H.S.
[Nm] Nome de substância:
0 (Oxidants); 0 (Waste Water); 0 (Water Pollutants, Chemical); 13AFD7670Q (Primidone); 17778-80-2 (Singlet Oxygen); 3352-57-6 (Hydroxyl Radical); 33CM23913M (Carbamazepine); 50VV3VW0TI (Atenolol); 6158TKW0C5 (Phenytoin); 9I7LNY769Q (Meprobamate)
[Em] Mês de entrada:1508
[Cu] Atualização por classe:141203
[Lr] Data última revisão:
141203
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:140507
[St] Status:MEDLINE


  8 / 1112 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:24790060
[Au] Autor:Bévalot F; Bottinelli C; Cartiser N; Fanton L; Guitton J
[Ad] Endereço:1 Laboratoire LAT LUMTOX, 71 Avenue Rockefeller, Lyon 69003, France.
[Ti] Título:Quantification of five compounds with heterogeneous physicochemical properties (morphine, 6-monoacetylmorphine, cyamemazine, meprobamate and caffeine) in 11 fluids and tissues, using automated solid-phase extraction and gas chromatography-tandem mass spectrometry.
[So] Source:J Anal Toxicol;38(5):256-64, 2014 Jun.
[Is] ISSN:1945-2403
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:An automated solid-phase extraction (SPE) protocol followed by gas chromatography coupled with tandem mass spectrometry was developed for quantification of caffeine, cyamemazine, meprobamate, morphine and 6-monoacetylmorphine (6-MAM) in 11 biological matrices [blood, urine, bile, vitreous humor, liver, kidney, lung and skeletal muscle, brain, adipose tissue and bone marrow (BM)]. The assay was validated for linearity, within- and between-day precision and accuracy, limits of quantification, selectivity, extraction recovery (ER), sample dilution and autosampler stability on BM. For the other matrices, partial validation was performed (limits of quantification, linearity, within-day precision, accuracy, selectivity and ER). The lower limits of quantification were 12.5 ng/mL(ng/g) for 6-MAM, morphine and cyamemazine, 100 ng/mL(ng/g) for meprobamate and 50 ng/mL(ng/g) for caffeine. Analysis of real-case samples demonstrated the performance of the assay in forensic toxicology to investigate challenging cases in which, for example, blood is not available or in which analysis in alternative matrices could be relevant. The SPE protocol was also assessed as an extraction procedure that could target other relevant analytes of interest. The extraction procedure was applied to 12 molecules of forensic interest with various physicochemical properties (alimemazine, alprazolam, amitriptyline, citalopram, cocaine, diazepam, levomepromazine, nordazepam, tramadol, venlafaxine, pentobarbital and phenobarbital). All drugs were able to be detected at therapeutic concentrations in blood and in the alternate matrices.
[Mh] Termos MeSH primário: Cafeína/análise
Cromatografia Gasosa-Espectrometria de Massas/métodos
Meprobamato/análise
Derivados da Morfina/análise
Morfina/análise
Fenotiazinas/análise
Extração em Fase Sólida/métodos
Espectrometria de Massas em Tandem/métodos
[Mh] Termos MeSH secundário: Limite de Detecção
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Morphine Derivatives); 0 (Phenothiazines); 3G6A5W338E (Caffeine); 76I7G6D29C (Morphine); 9I7LNY769Q (Meprobamate); A2JGV5CNU4 (cyamemazine); M5E47P1ZCH (6-O-monoacetylmorphine)
[Em] Mês de entrada:1501
[Cu] Atualização por classe:140509
[Lr] Data última revisão:
140509
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:140503
[St] Status:MEDLINE
[do] DOI:10.1093/jat/bku029


  9 / 1112 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:24488112
[Au] Autor:Tse SA; Atayee RS; Ma JD; Best BM
[Ad] Endereço:1Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego (UC San Diego), 9500 Gilman Drive, MC 0719, La Jolla, CA 92093-0719, USA.
[Ti] Título:Factors affecting carisoprodol metabolism in pain patients using urinary excretion data.
[So] Source:J Anal Toxicol;38(3):122-8, 2014 Apr.
[Is] ISSN:1945-2403
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Carisoprodol is a skeletal muscle relaxant prescribed to treat pain. Carisoprodol is metabolized to meprobamate, an active metabolite with anxiolytic effects, by the genetically polymorphic CYP2C19 enzyme. Concomitant use of CYP2C19 substrates or inhibitors may alter carisoprodol metabolism, with therapeutic and/or toxic implications for effectively treating patients with pain. This was a retrospective analysis of urinary excretion data collected from patients with pain from March 2008 to May 2011. Carisoprodol and meprobamate urine concentrations were measured by liquid chromatography-tandem mass spectrometry, and the metabolic ratio (MR) of meprobamate to carisoprodol concentrations was determined in 14,965 subjects. The MR geometric mean and 95% confidence interval (95% CI) of the young group (105, 95% CI = 99.1-113) were ∼47.4% higher than the middle-aged group (71.9, 95% CI = 70-73.8) and nearly two times higher than the elderly group (54.4, 95% CI = 51.3-57.6). Females had a 20.7% higher MR compared with males. No significant change in the MR was observed with overall CYP2C19 inhibitor or substrate use. However, evaluation of individual inhibitors showed co-administration with esomeprazole or fluoxetine was associated with a 31.8 and 24.6% reduction in MR, respectively, compared with controls (P < 0.05). Omeprazole did not significantly affect the MR. Patient-specific factors such as age, sex and co-medications may be important considerations for effective carisoprodol therapy.
[Mh] Termos MeSH primário: Carisoprodol/farmacocinética
Carisoprodol/urina
Relaxantes Musculares Centrais/farmacocinética
Relaxantes Musculares Centrais/urina
Dor/tratamento farmacológico
[Mh] Termos MeSH secundário: Adolescente
Adulto
Idoso
Idoso de 80 Anos ou mais
Hidrocarboneto de Aril Hidroxilases/antagonistas & inibidores
Hidrocarboneto de Aril Hidroxilases/metabolismo
Cromatografia Líquida
Citocromo P-450 CYP2C19
Relação Dose-Resposta a Droga
Interações Medicamentosas
Esomeprazol/administração & dosagem
Feminino
Fluoxetina/administração & dosagem
Seres Humanos
Masculino
Meprobamato/farmacocinética
Meprobamato/urina
Meia-Idade
Estudos Retrospectivos
Manejo de Espécimes
Espectrometria de Massas em Tandem
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Muscle Relaxants, Central); 01K63SUP8D (Fluoxetine); 21925K482H (Carisoprodol); 9I7LNY769Q (Meprobamate); EC 1.14.14.1 (Aryl Hydrocarbon Hydroxylases); EC 1.14.14.1 (CYP2C19 protein, human); EC 1.14.14.1 (Cytochrome P-450 CYP2C19); N3PA6559FT (Esomeprazole)
[Em] Mês de entrada:1411
[Cu] Atualização por classe:161125
[Lr] Data última revisão:
161125
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:140204
[St] Status:MEDLINE
[do] DOI:10.1093/jat/bku002


  10 / 1112 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
[PMID]:24446836
[Au] Autor:Zaïem A; Kaabi W; Badri T; Lakhoua G; Sahnoun R; Kastalli S; Daghfous R; Lakhal M; El Aidli S
[Ti] Título:Meprobamate-induced fixed drug eruption.
[So] Source:Curr Drug Saf;9(2):161-2, 2014.
[Is] ISSN:2212-3911
[Cp] País de publicação:United Arab Emirates
[La] Idioma:eng
[Ab] Resumo:Meprobamate is usually a safe drug prescribed for anxiety disorders. Fixed drug eruption (FDE) is an exceptional cutaneous adverse effect of this drug. We report a case of FDE induced by meprobamate with positive patch test. A 22-year-old woman was prescribed for depression meprobamate, aceprometazine, valpromide and lorazepam. On the second day of treatment, the patient presented red erythematous and pruriginous plaques in the limbs and the face. After stopping the previous treatment, the patient's lesions resolved completely within 3 weeks with residual pigmentation. One month later, patch tests were performed and were positive to meprobamate. Exceptional cases of FDE were reported in literature with meprobamate. None has reported the use of patch test to confirm the diagnosis.
[Mh] Termos MeSH primário: Erupção por Droga/etiologia
Meprobamato/efeitos adversos
[Mh] Termos MeSH secundário: Adulto
Feminino
Seres Humanos
Testes do Emplastro
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
9I7LNY769Q (Meprobamate)
[Em] Mês de entrada:1508
[Cu] Atualização por classe:141014
[Lr] Data última revisão:
141014
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:140123
[St] Status:MEDLINE



página 1 de 112 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde